Sublingual Immunotherapy and Eosinophilic Esophagitis (EoE)

EoE is a rare reported complication of sublingual immunotherapy. Because the allergen extract passes over the throat and esophagus on its way down, there is a recognized but uncommon link to eosinophilic inflammation in some individuals. It is important to keep the frequency in perspective: the vast majority of people on allergy drops never develop EoE, and the most common side effects are mild local mouth reactions. In the rare cases where SLIT appears to trigger esophageal inflammation, the symptoms generally resolve after stopping treatment. If you develop persistent difficulty swallowing or reflux-like symptoms after starting drops, report them to your provider, who can assess whether further evaluation is needed.

Pre-existing eosinophilic esophagitis is considered a contraindication for sublingual immunotherapy because the treatment delivers allergens across the lining of the mouth and esophagus, which could worsen the eosinophilic inflammation that defines EoE. Starting SLIT in someone who already has active EoE risks aggravating their condition. This is why a thorough medical history is part of determining candidacy. If you have been diagnosed with EoE, you should not begin allergy drops without specialist guidance. Your allergist and gastroenterologist can discuss whether any form of immunotherapy is appropriate and what monitoring would be required. Screening for conditions like EoE before starting is a standard part of safe care.

The most characteristic symptom of EoE is difficulty swallowing, often described as food feeling like it sticks on the way down or needing extra water to wash it down. Other symptoms include reflux-like chest or upper-abdominal discomfort, heartburn that does not respond to usual reflux treatment, and food regurgitation. In children, EoE may show up as feeding difficulty, poor weight gain, or food refusal. These symptoms tend to develop gradually rather than suddenly. Because they overlap with ordinary reflux, a definitive diagnosis requires an upper endoscopy with biopsy. If swallowing symptoms appear after starting allergy drops, stop dosing and contact your provider for guidance.

In the rare cases where sublingual immunotherapy appears to trigger eosinophilic esophagitis, the symptoms typically improve or resolve after the drops are discontinued. This reversibility is one of the reassuring features of treatment-associated EoE compared with other causes. That said, EoE is a medical diagnosis that should be confirmed and managed by a physician, often with an endoscopy and biopsy to document the inflammation and track its resolution. Do not assume that stopping the drops alone resolves the issue without follow-up. If you suspect EoE, work with your provider to confirm the diagnosis, stop the suspected trigger, and arrange appropriate monitoring to ensure the inflammation truly settles.

Eosinophilic esophagitis cannot be diagnosed from symptoms alone, because difficulty swallowing and reflux-like discomfort can have several causes. The definitive test is an upper endoscopy, in which a gastroenterologist passes a thin camera into the esophagus and takes small tissue samples, or biopsies. Those samples are examined under a microscope to count eosinophils; a high number confirms the diagnosis. The procedure may also reveal characteristic changes in the esophageal lining, such as rings or furrows. Because diagnosis requires this specialized testing, persistent swallowing symptoms should be evaluated by a physician rather than self-diagnosed. If you develop these symptoms while taking allergy drops, your provider can coordinate the appropriate referral and testing.